|Founder||Desh Bandhu Gupta|
|Vinita D. Gupta (CEO)|
Nilesh Gupta (MD)
|Products||Pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health|
|Revenue||₹158,585 million (US$2.2 billion) (2020)|
|₹7,572 million (US$110 million) (2020)|
|₹−2,693 million (US$−38 million) (2020)|
|Total assets||₹249,838 million (US$3.5 billion) (2020)|
|Total equity||₹92,252 million (US$1.3 billion) (2020)|
Number of employees
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai, Maharashtra, India. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.
History and evolution
Lupin was founded in 1968 by Desh Bandhu Gupta, who was a professor of chemistry at BITS-Pilani, Rajasthan. Gupta moved to Mumbai in the 60s to work on his business enterprise for which initially he had initially borrowed Rs 5000 from his wife to fund his venture. Subsequent funding from Central Bank of India, the company was able to start their manufacturing facility for producing folic acid and iron tablets for Government of India mother and child health program. Later Lupin started manufacturing anti TB drugs which at one point formed 36% of the company sales and was considered as the largest TB drugs manufacturer in the world.
After success with Lupin, in 1988 Gupta founded the group's CSR arm, the Lupin Human Welfare & Research Foundation (LHWRF). This initiative was dedicated to sustainable rural development with the aim to uplift families living below the poverty line.
The founder, Desh Bandhu Gupta died in June 2017 and was subsequently replaced as chairman by his wife, Manju Deshbandhu Gupta.
In October 2019, Pharma major lupin limited announced today the Appointment of Sreeji Gopinatham as Chief Information Officer (CIO).
In March 2019, the US FDA put several Lupin drug plants on notice for quality problems, and indicated it might not approve future Lupin drug applications.
Research and development
Lupin's research program covers the entire pharma product chain. The company's R&D program is headquartered in the Lupin Research Park located near Pune that houses over 1400 scientists. Lupin's R&D covers:
- Generics Research
- Process Research
- Pharmaceutical Research
- Advanced Drug Delivery Systems (ADDS) Research
- Intellectual Property Management
- Novel Drug Discovery and Development (NDDD)
- Biotechnology Research
Lupin's businesses encompass the entire pharmaceutical value chain, ranging from branded and generic formulations, APIs, advanced drug delivery systems to biotechnology. The company's drugs reach 70 countries with a footprint that covers advanced markets such as USA, Europe, Japan, Australia as well as emerging markets including India, the Philippines and South Africa to name a few.
Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals Inc. (LPI), the company's US subsidiary is a $891 million enterprise. It has a presence in the branded and generics markets of the US. In the branded business, Lupin operates in the CVS and Pediatric segments. The company is the market leader in 28 products out of the 77 products marketed in the US generics market, of which it is amongst the Top 3 by market share in 57 of these products (IMS Health, December 2014): Suprax (Cefixime), a paediatric antibiotic, is Lupin's top-selling product here. Other products in Lupin's branded portfolio include Antara< (Fenofibrate), Locoid lotion, Alinia (Nitazoxanide) and InspiraChambers (Anti-static valved holding chamber). The company is also the 5th largest and fastest growing generics player in the US (5.3% market share by prescriptions, IMS Health). Lupin's US brands business contributed 9% of total US sales whereas the generics business contributed 91% during FY 2014–15.
India Region Formulations (IRF)
Lupin's IRF business focuses on Lifestyle diseases and Chronic disease therapy segments, particularly in Cardiology, Central Nervous System (CNS), Diabetology, Anti-Asthma, Anti-Infective, Gastro Intestinal and Oncology. The IRF business contributed 24% of the company's overall revenues for FY 2014–15, growing by 20% and recording revenues of ₹29,676 million (US$420 million) for FY 2014-15 as compared to ₹24,794 million (US$350 million) for FY 2013–14.
It has 12 manufacturing plants and 2 Research plants in India, as Jammu(J&K), Mandideep & Indore (Madhya pradesh), Ankaleswar & Dabasa (Gujarat), Tarapur, Aurangabad and Nagpur (Maharashtra), Goa, Visakhapatnam (Andhra Pradesh) and Sikkim; where research centre at Pune and Aurangabad. Among these the baby plant is Nagpur plant which will the biggest formulation unit for Lupin in coming year.
Lupin's focus in the European Union encompasses Anti-Infectives, Cardiovascular, and CNS therapy areas, along with niche opportunities in segments like Oral Contraceptives, Dermatology and Ophthalmics. The company's presence in France is by way of a trade partnership; in Germany, it operates through its acquired entity Hormosan Pharma GmbH. ] (Hormosan); while the UK business is a direct-to-market initiative.
Lupin is the fastest-growing Top 10 generic pharmaceuticals player in Japan (IMS). It operates in Japan through its subsidiary, Kyowa Pharmaceutical Industry Co. Ltd. (Kyowa), a company acquired in 2007, and I’rom, Pharmaceutical Co. Ltd (IP), acquired in 2011. Kyowa has an active presence in Neurology, Cardiovascular, Gastroenterology and the Respiratory therapy segments. I'rom is a niche injectables company.
In 2014, Lupin entered into a strategic joint venture agreement with Toyama-based Japanese pharmaceuticals company, Yoshindo Inc. to create YL Biologics (YLB). YLB will be jointly managed by both partners and wil be responsible for conducting clinical development of certain biosimilars including regulatory fillings and obtaining marketing authorization in Japan.
Lupin's South African subsidiary, Pharma Dynamics (PD) is the fastest growing and the 4th largest generic company in the South African market (IMS). The company is a market leader in the Cardiovascular segment and has a growing presence in Neurology, Gastroenterology and the Over the Counter (OTC) segments.
Lupin entered the Australian market through its subsidiary, Generic Health Pte. Ltd. (GH). It subsequently acquired the worldwide marketing rights to the over-100-year-old Australian brand Goanna, used for pain management.
Lupin's Philippines subsidiary Multicare Pharmaceuticals (Multicare), is a branded generic company focused on Women's Health, Pediatrics, Gastro-Intestinal and Diabetes care. FY 2012 also marked its foray into the Neurology segment when it entered into a strategic marketing partnership with Sanofi.
Mexico & Latin America
In 2014, Lupin acquired 100% equity stake in Laboratories Grin, S.A. De C.V. (Grin), Mexico, a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of branded ophthalmic products. This marked their entry into Mexico and the larger Latin American pharmaceuticals market. In May 2015, Lupin entered the Brazilian market with its acquisition of 100% stake in Medquímica Indústria Farmacêutica S.A., Brazil, (Medquímica).
Lupin is a global leader in Cephalosporins, Cardiovasculars and the anti-TB space. The company is also a strategic supplier of anti-TB products to the Stop TB Partnership, with its formulations supplied to more than 50 countries through GDF procurement.
Rgwduen is also a global leader in anti-TB APIs, and is associated with the Revised National Tuberculosis Control Program of the Government of India. It supplies to various Government agencies, the Stop TB Partnership and various other international agencies like Pan American Health Organization (PAHO), Médecins Sans Frontières (MSF) and the Damien Foundation. Ethambutol, Rifampicin and Pyrazinamide are the company's top selling TB molecules.
The Lupin Biotechnology Research Group, based out of Ghotawade & Wakad, near Pune is focussed on developing biosimilars. As of May 2013, it has a pipeline of 10 biosimilar products under development, and is close to getting marketing authorization for 2 of its oncology products for the Indian market. Lupin has competencies for the complete development and manufacture of recombinant protein therapeutic products from high yielding and proprietary microbial and mammalian cell culture platforms. The Biotech R&D infrastructure offers a range of product development capabilities ranging from clone development, process optimization, analytical method development, bioassay, formulation, stability studies, non-clinical and clinical studies backed by a sound understanding of regulatory and IP aspects. The company's biotech development programs are in compliance of and follow IC, EMEA, and Indian Regulatory guidelines.
The Lupin Human Welfare & Research Foundation (LHWRF) was set up in 1988. The project began with a set of rural development projects centred around 35 villages in Bharatpur District, Rajasthan. Later this expanded to other regions and states. The initiative has so far reached out to over 2.8 million people across over 3,400 villages in eight states of India including Rajasthan, Madhya Pradesh, Maharashtra, Uttarakhand, Gujarat and Goa. In July 2018, Lupin foundation signed a statement of Intent with the National Institution for Transforming India (Niti Aayog), a policy think tank of the government of India, to collaborate in the Aspirational Districts Programme and support the development of three backward districts – Nandurbar in Maharashtra, Vidisha in Madhya Pradesh and Dholpur in Rajasthan.
- "Welcome to Lupin World". Lupinworld.com. Archived from the original on 8 June 2012. Retrieved 30 May 2013.
- "Lupin goes all out to make up for lost chances - Corporate News". livemint.com. 8 February 2010. Retrieved 30 September 2010.
- "Welcome to Lupin World". Lupinworld.com. Archived from the original on 7 June 2013. Retrieved 30 May 2013.
- "Lupin outcome of board meeting". moneycontrol.com.
- "Lupin Limited Annual Report 2020" (PDF). Lupin Limited. Retrieved 2 July 2019.
- "Top five generic drug makers". europeanpharmaceuticalreview.com. Retrieved 22 May 2020.
- Megha Bahree. "Desh Bandhu Gupta". Forbes.
- "Guru of Generics- Business News". businesstoday.in. Retrieved 8 April 2019.
- Bhatia, Navin (26 June 2017). "How Desh Bandhu Gupta Turned A Rs. 5000 Loan Into The Rs. 18,000 Crore Pharmaceutical Giant, Lupin". OfficeChai. Retrieved 8 April 2019.
- Ketaki Gokhale (23 July 2015). "Lupin to Buy Gavis in $880 Million Deal to Expand in U.S." Bloomberg.com.
- PTI (11 August 2017). "Lupin appoints Manju Deshbandhu Gupta as chairman". Mint. Retrieved 8 April 2019.
- "Sreeji Gopinathan joins Lupin as Chief Information Officer". Medical Dialogues. 10 October 2019.
- "Lupin transforms into a global pharma company". timesofindia-economictimes. 30 April 2010.
- "Forbes India Magazine - The Japanese Are a Brand Conscious People, Says Lupin MD". forbesindia.com.
- P. T. Jyothi Datta. "Lupin looks at big-ticket alliances, acquisition in India". The Hindu Business Line.
- "Lupin". lupinworld.com.
- "Lupin". lupinworld.com. Archived from the original on 25 February 2001. Retrieved 30 September 2010.
- "Lupin acquires Germany-based Hormosan Pharma". livemint.com.
- BS Reporter (11 October 2007). "Lupin buys Japan's Kyowa Pharma". business-standard.com.
- Watts, Himangshu (10 October 2007). "India's Lupin says acquires Japan's Kyowa Pharma". Reuters.
- "Lupin acquires Japan's I'rom Pharma". indianexpress.com.
- "Lupin to acquire Japan's I'rom Pharma". Firstpost.
- C. H. Unnikrishnan. "Lupin, Yoshindo form JV for clinical development of biosimilars in Japan". livemint.com.
- "Lupin completes acquisition of Pharma Dynamics – The Financial Express". The Financial Express. 16 March 2015.
- Press Trust of India (29 September 2010). "Lupin acquires majority stake in Australian firm". business-standard.com.
- "Lupin acquires global rights for Australian brand Goanna". timesofindia-economictimes. 15 June 2011.
- "Pharma - Lupin buys Philippines drug firm Multicare". livemint.com.
- "Lupin, Sanofi-Aventis ink drug marketing pact in Philippines". livemint.com.
- "Lupin acquires Brazilian drug firm Medquimica". timesofindia-economictimes. 13 May 2015.
- "Niti Aayog and Lupin foundation sign SoI". pib.nic.in (GOI press release).